Molecular Templates, Inc. (MTEM) News

Molecular Templates, Inc. (MTEM): $6.20

0.13 (+2.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MTEM News Items

MTEM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MTEM News From Around the Web

Below are the latest news stories about Molecular Templates Inc that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -115.38% and -50.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 13, 2021

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

Intrado Digital Media | August 12, 2021

10 Best Biotech Stocks to Buy According to Alan Frazier’s Frazier Healthcare Partners

In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier. If you want to skip our detailed analysis of Frazier’s history and hedge fund performance, go directly to the 5 Best Biotech Stocks to Buy According to Alan Frazier. Alan Frazier established Frazier Healthcare Partners in 1991. During his […]

Yahoo | August 5, 2021

Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

Molecular Templates, Inc. (MTEM) Fell Out Of Favor With Hedge Funds?

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Yahoo | July 21, 2021

Here's What Molecular Templates, Inc.'s (NASDAQ:MTEM) Shareholder Ownership Structure Looks Like

The big shareholder groups in Molecular Templates, Inc. ( NASDAQ:MTEM ) have power over the company. Large companies...

Yahoo | July 19, 2021

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: A...

Benzinga | July 15, 2021

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors. “We are excited to have dosed the first subject in the Phase 1 study for MT-64

Yahoo | July 9, 2021

Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.

Intrado Digital Media | July 6, 2021

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. “Dr. Sanders’ established experience in globa

Yahoo | June 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7195 seconds.